{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T06:01:19.194892+00:00","company":{"ticker":"STAA","cik":718937,"company_name":"STAAR SURGICAL CO"},"pagination":{"limit":100,"returned":48,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Alcon Research, LLC","detail":"merger","count":1,"first_seen":"2026-01-06T23:59:59+00:00","last_seen":"2026-01-06T23:59:59+00:00","evidence_fact_ids":[36149]},{"display_name":"Alcon Research, LLC and Rascasse Merger Sub, Inc.","detail":"merger","count":1,"first_seen":"2025-12-09T23:59:59+00:00","last_seen":"2025-12-09T23:59:59+00:00","evidence_fact_ids":[130096]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"eecca510c0c3f9b0d03094a4c1bf76aca28e440b","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-06-22T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,406,114","subject":null,"votes_abstain":"82,750","votes_against":"1,454,186","votes_for":"39,737,385","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers.","evidence_excerpt":"Proposal 4 : To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes 39,737,385 1,454,186 82,750 2,406,114","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000718937-26-000029","anchor_url":"https://secwatch.observer/filing/0000718937-26-000029#claim-eecca510c0c3f9b0d03094a4c1bf76aca28e440b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000029/0000718937-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"11e6e416dd1ba643218ba83c2809bec7864539c5","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-06-22T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2027-01-01","outcome":"passed","proposal_text":"To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,050","votes_against":"237,151","votes_for":"43,433,234","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027 at the 2027-01-01 meeting.","evidence_excerpt":"Proposal 3 : To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027: Number of Shares For Against Abstain Broker Non-Votes 43,433,234 237,151 10,050 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000718937-26-000029","anchor_url":"https://secwatch.observer/filing/0000718937-26-000029#claim-11e6e416dd1ba643218ba83c2809bec7864539c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000029/0000718937-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"29a6bbf97845a52bd023c1499d6db2856fc6e986","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-06-22T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,406,114","subject":null,"votes_abstain":"67,857","votes_against":"974,989","votes_for":"40,231,475","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares.","evidence_excerpt":"Proposal 2: To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares: Number of Shares For Against Abstain Broker Non-Votes 40,231,475 974,989 67,857 2,406,114","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000718937-26-000029","anchor_url":"https://secwatch.observer/filing/0000718937-26-000029#claim-29a6bbf97845a52bd023c1499d6db2856fc6e986","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000029/0000718937-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"09185e5168405f61a87ac2cc3287270a2c9240a5","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-06-22T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"2,406,114","subject":"Neal C. Bradsher","votes_abstain":null,"votes_against":null,"votes_for":"40,776,719","votes_withheld":"497,602"},{"broker_non_votes":"2,406,114","subject":"Arthur C. Butcher","votes_abstain":null,"votes_against":null,"votes_for":"40,565,567","votes_withheld":"708,754"},{"broker_non_votes":"2,406,114","subject":"Wei Jiang","votes_abstain":null,"votes_against":null,"votes_for":"41,098,173","votes_withheld":"176,148"},{"broker_non_votes":"2,406,114","subject":"Richard T. LeBuhn","votes_abstain":null,"votes_against":null,"votes_for":"41,170,957","votes_withheld":"103,364"},{"broker_non_votes":"2,406,114","subject":"Louis E. Silverman","votes_abstain":null,"votes_against":null,"votes_for":"40,487,195","votes_withheld":"787,126"},{"broker_non_votes":"2,406,114","subject":"Christopher M. Wang","votes_abstain":null,"votes_against":null,"votes_for":"40,941,468","votes_withheld":"332,853"},{"broker_non_votes":"2,406,114","subject":"Lilian Y. Zhou","votes_abstain":null,"votes_against":null,"votes_for":"40,488,276","votes_withheld":"786,045"}]},"claim":"STAAR SURGICAL CO shareholders approved To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified.","evidence_excerpt":"Proposal 1: To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified: Number of Shares For Withheld Broker Non-Votes Neal C. Bradsher 40,776,719 497,602 2,406,114 Arthur C. Butcher 40,565,567 708,754 2,406,114 Wei Jiang 41,098,173 176,148 2,406,114 Richard T. LeBuhn 41,170,957 103,364 2,406,114 Louis E. Silverman 40,487,195 787,126 2,406,114 Christopher M. Wang 40,941,468 332,853 2,406,114 Lilian Y. Zhou 40,488,276 786,045 2,406,114","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000718937-26-000029","anchor_url":"https://secwatch.observer/filing/0000718937-26-000029#claim-09185e5168405f61a87ac2cc3287270a2c9240a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000029/0000718937-26-000029-index.htm"},{"fact_type":"earnings_release","fact_key":"f6b16fbae2282916cc7108833df0bfc47b568542","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-05-13T20:02:18+00:00","payload":{"eps_text":"$0.10","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.2 million","period_text":"First Quarter 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":"$93.5 million"},"claim":"STAAR SURGICAL CO reported First Quarter 2026 results: revenue $93.5 million, net income $5.2 million, EPS $0.10.","evidence_excerpt":"STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter Net Sales of $93.5 million, highest first quarter Net Sales in Company’s history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000718937-26-000022","anchor_url":"https://secwatch.observer/filing/0000718937-26-000022#claim-f6b16fbae2282916cc7108833df0bfc47b568542","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000022/0000718937-26-000022-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4e3101193968b0fe8ab34c2a7b8d5cd4b4110696","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-01-15T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-01-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5605(c)(4)(B)"],"rules_cited_in_text":true},"claim":"STAAR SURGICAL CO received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(4)(B)).","evidence_excerpt":"January 14, 2026, Elizabeth Yeu, MD resigned from the Board. Among other things, NASDAQ Listing Rule 5605 requires listed issuers such as the Company to maintain an audit committee consisting of no fewer than three independent directors. Dr. Yeu had been one of three independent directors on the Company’s Audit Committee at the time of her resignation, and therefore the Company does not presently comply with such requirement. In accordance with the Listing Rules, the Company notified NASDAQ on January 14, 2026 of such noncompliance and the Company’s intention to use the cure period provided un","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-013622","anchor_url":"https://secwatch.observer/filing/0001193125-26-013622#claim-4e3101193968b0fe8ab34c2a7b8d5cd4b4110696","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312526013622/0001193125-26-013622-index.htm"},{"fact_type":"material_agreement","fact_key":"48cecef5e6b98230165c10582a9544850b605c02","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2026-01-06T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"Alcon Research, LLC","effective_date":"2026-01-06","item_codes_triggered":["1.02"],"value_text":null},"claim":"STAAR SURGICAL CO terminated Agreement and Plan of Merger with Alcon Research, LLC (effective 2026-01-06).","evidence_excerpt":"As previously disclosed, on August 4, 2025, STAAR Surgical Company (the “Company”) entered into an Agreement and Plan of Merger, dated as of August 4, 2025 (as amended, the “Merger Agreement”), by and among the Company, Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-004699","anchor_url":"https://secwatch.observer/filing/0001193125-26-004699#claim-48cecef5e6b98230165c10582a9544850b605c02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312526004699/0001193125-26-004699-index.htm"},{"fact_type":"material_agreement","fact_key":"04fcef7611d58d387115afbe63a26d732741d85f","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-12-09T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 2","agreement_type":"merger","counterparty":"Alcon Research, LLC and Rascasse Merger Sub, Inc.","effective_date":"2025-12-09","item_codes_triggered":["1.01"],"value_text":"$30.75 per share"},"claim":"STAAR SURGICAL CO amended Amendment No. 2 with Alcon Research, LLC and Rascasse Merger Sub, Inc. valued at $30.75 per share (effective 2025-12-09).","evidence_excerpt":"On December 9, 2025, STAAR Surgical Company (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Agreement and Plan of Merger, dated August 4, 2025 (as amended, the “Amended Merger Agreement”), with Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc. (“Merger Sub”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-311982","anchor_url":"https://secwatch.observer/filing/0001193125-25-311982#claim-04fcef7611d58d387115afbe63a26d732741d85f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312525311982/0001193125-25-311982-index.htm"},{"fact_type":"executive_change","fact_key":"004509e8a2","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-06-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-25","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Deborah Andrews was appointed as Chief Financial Officer at STAAR SURGICAL CO.","evidence_excerpt":"On June 25, 2025, STAAR Surgical Company (the “Company”) announced that its Board of Directors (the “Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-089733","anchor_url":"https://secwatch.observer/filing/0000950170-25-089733#claim-004509e8a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025089733/0000950170-25-089733-index.htm"},{"fact_type":"executive_change","fact_key":"8a3537a3ec","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-04-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-24","interim":true,"role":"Chief of APAC Strategy","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Wei Jiang was appointed as Chief of APAC Strategy at STAAR SURGICAL CO.","evidence_excerpt":"the Company entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Company’s Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-058173","anchor_url":"https://secwatch.observer/filing/0000950170-25-058173#claim-8a3537a3ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025058173/0000950170-25-058173-index.htm"},{"fact_type":"executive_change","fact_key":"06a756f8cb","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-04-24T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Aimee S. Weisner departed as director at STAAR SURGICAL CO.","evidence_excerpt":"Ms. Weisner notified the Company that she has chosen not to stand for re-election when her term expires at the 2025 Annual Meeting","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-058173","anchor_url":"https://secwatch.observer/filing/0000950170-25-058173#claim-06a756f8cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025058173/0000950170-25-058173-index.htm"},{"fact_type":"executive_change","fact_key":"bde4c2954c","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-04-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-24","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Louis E. Silverman was appointed as director at STAAR SURGICAL CO.","evidence_excerpt":"the Board appointed Louis E. Silverman, who served on the Company’s Board from 2014-2022, as a director, effective April 24, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-058173","anchor_url":"https://secwatch.observer/filing/0000950170-25-058173#claim-bde4c2954c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025058173/0000950170-25-058173-index.htm"},{"fact_type":"governance_change","fact_key":"6b10d84bdb14b9aeb07334737edd2f5a480f8700","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-03-17","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to revise officer provisions including renaming Chairman to Chair of the Board, allowing separate CEO and President, establishing CFO as an officer, and making other changes for flexibility in officer appointments."},"claim":"STAAR SURGICAL CO: Amended and restated bylaws to revise officer provisions including renaming Chairman to Chair of the Board, allowing separate CEO and President, establishing CFO as an officer, and making other changes for flexibility in officer appointments (effective 2025-03-17).","evidence_excerpt":"Effective as of the Effective Date, the Board approved and adopted the amended and restated bylaws of the Company to reflect the amendments summarized herein (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-6b10d84bdb14b9aeb07334737edd2f5a480f8700","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"a827c04809","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"will no longer hold the title of President","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-17","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Stephen C. Farrell changed role as Chief Executive Officer at STAAR SURGICAL CO.","evidence_excerpt":"Mr. Stephen C. Farrell will continue to serve as the Chief Executive Officer of the Company and as a member of the Company’s Board but, effective as of the Effective Date, will no longer hold the title of President of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-a827c04809","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"85b97eb7a9","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-03-17","interim":false,"role":"Chief Technology Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Keith Holliday departed as Chief Technology Officer at STAAR SURGICAL CO.","evidence_excerpt":"Keith Holliday, PhD has agreed to retire, effective as of the Effective Date, at the request of the Board from his position as Chief Technology Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-85b97eb7a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"519fa4ff56","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-17","interim":false,"role":"Chief Development Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Magda Michna was appointed as Chief Development Officer at STAAR SURGICAL CO.","evidence_excerpt":"the Board appointed Magda Michna, PhD, the Company’s Chief Clinical, Regulatory and Medical Affairs Officer, to the newly created role of Chief Development Officer","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-519fa4ff56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"b16ae47e35","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-17","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Deborah Andrews was appointed as Interim Chief Financial Officer at STAAR SURGICAL CO.","evidence_excerpt":"the Board appointed Deborah Andrews, the Company’s former Chief Financial Officer, to serve as the Company’s Interim Chief Financial Officer and principal accounting officer on an interim basis, effective as of the Effective Date","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-b16ae47e35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"2d3db02b8c","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"step down","action_category":"departure","departure_tone":"abrupt","effective_date":"2025-03-17","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Deborah Andrews","successor_named":true},"claim":"Patrick Williams departed as Chief Financial Officer at STAAR SURGICAL CO.","evidence_excerpt":"Patrick Williams has agreed to step down, effective as of the same date, at the request of the Board from his position as Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-2d3db02b8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"d836aeb07c","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-17","interim":false,"role":"President and Chief Operating Officer","role_category":"president","successor_name":null,"successor_named":false},"claim":"Warren Foust was appointed as President and Chief Operating Officer at STAAR SURGICAL CO.","evidence_excerpt":"the Board appointed the Company’s Chief Operating Officer, Warren Foust, as President and Chief Operating Officer of the Company, effective March 17, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040620","anchor_url":"https://secwatch.observer/filing/0000950170-25-040620#claim-d836aeb07c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/0000950170-25-040620-index.htm"},{"fact_type":"executive_change","fact_key":"4acf065ab4","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-02-26T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-26","interim":false,"role":"Board Chair","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Elizabeth Yeu was elected as Board Chair at STAAR SURGICAL CO.","evidence_excerpt":"the Board elected Director Elizabeth Yeu, M.D., to serve as Board Chair, effective as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-027880","anchor_url":"https://secwatch.observer/filing/0000950170-25-027880#claim-4acf065ab4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025027880/0000950170-25-027880-index.htm"},{"fact_type":"executive_change","fact_key":"e6030bb1fe","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-02-26T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"abrupt","effective_date":"2025-02-26","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Stephen C. Farrell","successor_named":true},"claim":"Thomas G. Frinzi departed as President and Chief Executive Officer at STAAR SURGICAL CO.","evidence_excerpt":"Effective as the Effective Date, Mr. Frinzi has agreed to step down at the request of the Board from his positions as President and Chief Executive Officer, and he will cease to serve as a member of the Board of Directors and Board Chair and all other positions with the Company and its subsidiaries.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-027880","anchor_url":"https://secwatch.observer/filing/0000950170-25-027880#claim-e6030bb1fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025027880/0000950170-25-027880-index.htm"},{"fact_type":"executive_change","fact_key":"a595134307","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2025-02-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-26","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Stephen C. Farrell was appointed as President and Chief Executive Officer at STAAR SURGICAL CO.","evidence_excerpt":"the Board appointed Stephen C. Farrell to succeed Thomas G. Frinzi as President and Chief Executive Officer, effective February 26, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-027880","anchor_url":"https://secwatch.observer/filing/0000950170-25-027880#claim-a595134307","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017025027880/0000950170-25-027880-index.htm"},{"fact_type":"earnings_release","fact_key":"8da30ae9052c18ebdf81aa563cdba8b8ca0a9378","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.07 loss per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $3.3 million or $0.07 loss per share","period_text":"first quarter ended March 29, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$77.4 million"},"claim":"STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue $77.4 million, net income Net loss of $3.3 million or $0.07 loss per share, EPS $0.07 loss per share. Guidance reaffirmed.","evidence_excerpt":"(EVO ICLTM) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview • Net sales up 5% to $77.4 million and up 7% in constant currency • ICL sales up 9% and units up 2% • Gross margin at 78.9% vs. 78.3% year ago • Net loss of $3.3 million or $0.07 loss per share vs. net income of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-054454","anchor_url":"https://secwatch.observer/filing/0000950170-24-054454#claim-8da30ae9052c18ebdf81aa563cdba8b8ca0a9378","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm"},{"fact_type":"earnings_release","fact_key":"333ac7ad511d54bab0b5cda2cdb475dbf49cb01b","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-04-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 29, 2024","report_date":"2024-04-04","result_type":"preliminary_results","revenue_text":"in excess of $77 million"},"claim":"STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue in excess of $77 million.","evidence_excerpt":"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million, with U.S. ICL sales expected to be $5 million for the quarter.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-041613","anchor_url":"https://secwatch.observer/filing/0000950170-24-041613#claim-333ac7ad511d54bab0b5cda2cdb475dbf49cb01b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/0000950170-24-041613-index.htm"},{"fact_type":"executive_change","fact_key":"99230f8659","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-03-12T23:59:59+00:00","payload":{"action":"does not intend to stand for re-election","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"K. Peony Yu departed as Director at STAAR SURGICAL CO.","evidence_excerpt":"director K. Peony Yu has indicated that she does not intend to stand for re-election to the Board upon the expiration of her term as a director at the Corporation’s 2024 Annual Meeting of Shareholders","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-029647","anchor_url":"https://secwatch.observer/filing/0000950170-24-029647#claim-99230f8659","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024029647/0000950170-24-029647-index.htm"},{"fact_type":"executive_change","fact_key":"c06ec4cbb4","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-03-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Wei Jiang was appointed as Director at STAAR SURGICAL CO.","evidence_excerpt":"the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) voted to increase the size of the Board from six (6) directors to eight (8) directors and appointed to the Board two new directors, Arthur Butcher and Wei Jiang, effective March 12, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-029647","anchor_url":"https://secwatch.observer/filing/0000950170-24-029647#claim-c06ec4cbb4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024029647/0000950170-24-029647-index.htm"},{"fact_type":"executive_change","fact_key":"16c0a6cecc","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-03-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Arthur Butcher was appointed as Director at STAAR SURGICAL CO.","evidence_excerpt":"the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) voted to increase the size of the Board from six (6) directors to eight (8) directors and appointed to the Board two new directors, Arthur Butcher and Wei Jiang, effective March 12, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-029647","anchor_url":"https://secwatch.observer/filing/0000950170-24-029647#claim-16c0a6cecc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024029647/0000950170-24-029647-index.htm"},{"fact_type":"earnings_release","fact_key":"5993a10abab4bd967278463f2876c6d2b46d8891","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 29, 2023","report_date":"2024-02-26","result_type":"reported_results","revenue_text":null},"claim":"STAAR SURGICAL CO updated its the quarter and year ended December 29, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 26, 2024, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and year ended December 29, 2023, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-020126","anchor_url":"https://secwatch.observer/filing/0000950170-24-020126#claim-5993a10abab4bd967278463f2876c6d2b46d8891","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024020126/0000950170-24-020126-index.htm"},{"fact_type":"earnings_release","fact_key":"332ee6b908e44803950cf1d089910a81c41277c6","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year ended December 29, 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":"Net sales of approximately $322.5 million for fiscal 2023 (preliminary)"},"claim":"STAAR SURGICAL CO reported fiscal year ended December 29, 2023 results: revenue Net sales of approximately $322.5 million for fiscal 2023 (preliminary). Guidance initiated.","evidence_excerpt":"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-002738","anchor_url":"https://secwatch.observer/filing/0000950170-24-002738#claim-332ee6b908e44803950cf1d089910a81c41277c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm"},{"fact_type":"executive_change","fact_key":"441da43374","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-12-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-01","interim":false,"role":"Director","role_category":"director","successor_name":"Lillian Zhou","successor_named":true},"claim":"Gilbert Kliman resigned as Director at STAAR SURGICAL CO.","evidence_excerpt":"On December 1, 2023, Gilbert Kliman, MD, submitted his resignation as a Director of the Company, effective December 1, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-067757","anchor_url":"https://secwatch.observer/filing/0000950170-23-067757#claim-441da43374","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023067757/0000950170-23-067757-index.htm"},{"fact_type":"executive_change","fact_key":"860ffa72ce","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-12-04T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lillian Zhou was elected as Director at STAAR SURGICAL CO.","evidence_excerpt":"On December 1, 2023, the Board of Directors of STAAR Surgical Company (the “Company”) elected Lillian Zhou, 41, to serve as a member of the Board of Directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-067757","anchor_url":"https://secwatch.observer/filing/0000950170-23-067757#claim-860ffa72ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023067757/0000950170-23-067757-index.htm"},{"fact_type":"earnings_release","fact_key":"fafe136737d06d1e472993bf85a06e3847cb960e","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-11-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 29, 2023","report_date":"2023-11-01","result_type":"reported_results","revenue_text":null},"claim":"STAAR SURGICAL CO reported financial results for the quarter ended September 29, 2023.","evidence_excerpt":"On November 1, 2023, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended September 29, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-057446","anchor_url":"https://secwatch.observer/filing/0000950170-23-057446#claim-fafe136737d06d1e472993bf85a06e3847cb960e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023057446/0000950170-23-057446-index.htm"},{"fact_type":"earnings_release","fact_key":"a6fce35768bc861fba14ff35d97bc6fb0aef096f","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-08-02T23:59:59+00:00","payload":{"eps_text":"$0.12 per diluted share","guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":"$6.1 million or $0.12 per diluted share","period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-02","result_type":"reported_results","revenue_text":"$92.3 million"},"claim":"STAAR SURGICAL CO reported the second quarter ended June 30, 2023 results: revenue $92.3 million, net income $6.1 million or $0.12 per diluted share, EPS $0.12 per diluted share. Guidance lowered.","evidence_excerpt":"and\nmarketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023\nOverview • Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products • Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency • ICL Units Up 21% Y/Y","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-23-201709","anchor_url":"https://secwatch.observer/filing/0001193125-23-201709#claim-a6fce35768bc861fba14ff35d97bc6fb0aef096f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/0001193125-23-201709-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8e4051fb6797a429cea0e0b8dc338c8f7bc4d647","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"To hold an advisory vote on the frequency of future advisory votes to approve named executive officer compensation.","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"62,538","votes_against":null,"votes_for":"37,181,625","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To hold an advisory vote on the frequency of future advisory votes to approve named executive officer compensation. at the 2023-06-15 meeting.","evidence_excerpt":"To hold an advisory vote on the frequency of future advisory votes to approve named executive officer compensation.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-028687","anchor_url":"https://secwatch.observer/filing/0000950170-23-028687#claim-8e4051fb6797a429cea0e0b8dc338c8f7bc4d647","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023028687/0000950170-23-028687-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0603a0bb46c4b8e00361a894c7160fcd4705cfa0","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"To hold an advisory vote to approve STAAR’s compensation of its named executive officers.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,529,674","subject":null,"votes_abstain":"74,938","votes_against":"1,838,486","votes_for":"35,577,495","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To hold an advisory vote to approve STAAR’s compensation of its named executive officers. at the 2023-06-15 meeting.","evidence_excerpt":"To hold an advisory vote to approve STAAR’s compensation of its named executive officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-028687","anchor_url":"https://secwatch.observer/filing/0000950170-23-028687#claim-0603a0bb46c4b8e00361a894c7160fcd4705cfa0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023028687/0000950170-23-028687-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2a2ec5c1664d87f56a134eb3fe4bdcaa11358800","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"To ratify the selection of BDO USA, LLP as the Company’s independent registered public accountants for the fiscal year ending December 29, 2023.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"4,056,290","votes_against":"846,605","votes_for":"35,117,698","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To ratify the selection of BDO USA, LLP as the Company’s independent registered public accountants for the fiscal year ending December 29, 2023. at the 2023-06-15 meeting.","evidence_excerpt":"To ratify the selection of BDO USA, LLP as the Company’s independent registered public accountants for the fiscal year ending December 29, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-028687","anchor_url":"https://secwatch.observer/filing/0000950170-23-028687#claim-2a2ec5c1664d87f56a134eb3fe4bdcaa11358800","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023028687/0000950170-23-028687-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c78e4dd1d93c23448720f8f1ba6ec8054049519a","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"To approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,529,674","subject":null,"votes_abstain":"52,154","votes_against":"1,235,651","votes_for":"36,203,114","votes_withheld":null}]},"claim":"STAAR SURGICAL CO shareholders approved To approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan. at the 2023-06-15 meeting.","evidence_excerpt":"To approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-028687","anchor_url":"https://secwatch.observer/filing/0000950170-23-028687#claim-c78e4dd1d93c23448720f8f1ba6ec8054049519a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023028687/0000950170-23-028687-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6d81bc65cd4c13ec315f851b9722e12bd34d0fd5","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"To elect six directors to serve for terms to expire in 2024 or until their successors have been elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"2,529,674","subject":"Stephen C. Farrell","votes_abstain":null,"votes_against":null,"votes_for":"36,514,871","votes_withheld":"976,048"},{"broker_non_votes":"2,529,674","subject":"Thomas G. Frinzi","votes_abstain":null,"votes_against":null,"votes_for":"36,532,371","votes_withheld":"958,548"},{"broker_non_votes":"2,529,674","subject":"Gilbert H. Kliman, MD","votes_abstain":null,"votes_against":null,"votes_for":"26,759,870","votes_withheld":"10,731,049"},{"broker_non_votes":"2,529,674","subject":"Aimee S. Weisner","votes_abstain":null,"votes_against":null,"votes_for":"35,367,873","votes_withheld":"2,123,046"},{"broker_non_votes":"2,529,674","subject":"Elizabeth Yeu, MD","votes_abstain":null,"votes_against":null,"votes_for":"36,496,280","votes_withheld":"994,639"},{"broker_non_votes":"2,529,674","subject":"K. Peony Yu, MD","votes_abstain":null,"votes_against":null,"votes_for":"36,680,322","votes_withheld":"810,597"}]},"claim":"STAAR SURGICAL CO shareholders approved To elect six directors to serve for terms to expire in 2024 or until their successors have been elected and qualified. at the 2023-06-15 meeting.","evidence_excerpt":"To elect six directors to serve for terms to expire in 2024 or until their successors have been elected and qualified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-028687","anchor_url":"https://secwatch.observer/filing/0000950170-23-028687#claim-6d81bc65cd4c13ec315f851b9722e12bd34d0fd5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023028687/0000950170-23-028687-index.htm"},{"fact_type":"earnings_release","fact_key":"afc31751cd610b1473bae4c468df57f862cb7ed2","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-05-03T23:59:59+00:00","payload":{"eps_text":"$0.05 per diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$2.7 million or $0.05 per diluted share","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-03","result_type":"reported_results","revenue_text":"$73.5 million"},"claim":"STAAR SURGICAL CO reported first quarter ended March 31, 2023 results: revenue $73.5 million, net income $2.7 million or $0.05 per diluted share, EPS $0.05 per diluted share. Guidance raised.","evidence_excerpt":"in the filing unless specifically stated so therein . \n\n--- EX-99 (EX-99.1) ---\n\nEX-99 Exhibit 99.1 STAAR Surgical Reports First Quarter 2023 Results Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y LAKE FOREST, CA, May 3, 2023 --- STAAR Surgical","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-017172","anchor_url":"https://secwatch.observer/filing/0000950170-23-017172#claim-afc31751cd610b1473bae4c468df57f862cb7ed2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023017172/0000950170-23-017172-index.htm"},{"fact_type":"executive_change","fact_key":"65aabee572","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-03-29T23:59:59+00:00","payload":{"action":"named","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-04-24","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Warren Foust was named as Chief Operating Officer at STAAR SURGICAL CO.","evidence_excerpt":"On March 29, 2023, STAAR Surgical Company (the “Company”) announced that it named Mr. Warren Foust, age 47, to serve in the newly created role of Chief Operating Officer (COO), effective April 24, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-23-010431","anchor_url":"https://secwatch.observer/filing/0000950170-23-010431#claim-65aabee572","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017023010431/0000950170-23-010431-index.htm"},{"fact_type":"earnings_release","fact_key":"77faf5d25fc3d82586f86474017c80826eda0528","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-02-21T23:59:59+00:00","payload":{"eps_text":"$0.12 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$0.12 per diluted share","period_text":"fourth quarter and fiscal year ended December 30, 2022","report_date":"2023-02-21","result_type":"reported_results","revenue_text":"$64.0 million"},"claim":"STAAR SURGICAL CO reported fourth quarter and fiscal year ended December 30, 2022 results: revenue $64.0 million, net income $0.12 per diluted share, EPS $0.12 per diluted share. Guidance reaffirmed.","evidence_excerpt":"of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview • Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter • ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21%","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-002118","anchor_url":"https://secwatch.observer/filing/0001564590-23-002118#claim-77faf5d25fc3d82586f86474017c80826eda0528","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/0001564590-23-002118-index.htm"},{"fact_type":"governance_change","fact_key":"12fd399273608e9d17c0f851399e57ecb2fa4178","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-02-01T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-01-26","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to update procedural mechanics, enhance director nominee requirements, add exclusive forum provision, etc."},"claim":"STAAR SURGICAL CO: Amended and restated bylaws to update procedural mechanics, enhance director nominee requirements, add exclusive forum provision, etc (effective 2023-01-26).","evidence_excerpt":"On January 26, 2023, the Board of Directors of STAAR Surgical Company (the “Company”) adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the \"Amended and Restated Bylaws\"), effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-001300","anchor_url":"https://secwatch.observer/filing/0001564590-23-001300#claim-12fd399273608e9d17c0f851399e57ecb2fa4178","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459023001300/0001564590-23-001300-index.htm"},{"fact_type":"earnings_release","fact_key":"db4c365935f282b6c6a1e83915e93ca2c8f9641e","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2023-01-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 30, 2022","report_date":"2023-01-09","result_type":"preliminary_results","revenue_text":"approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022"},"claim":"STAAR SURGICAL CO reported the fourth quarter and fiscal year ended December 30, 2022 results: revenue approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022. Guidance initiated.","evidence_excerpt":"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022. Preliminary net sales were approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000271","anchor_url":"https://secwatch.observer/filing/0001564590-23-000271#claim-db4c365935f282b6c6a1e83915e93ca2c8f9641e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459023000271/0001564590-23-000271-index.htm"},{"fact_type":"executive_change","fact_key":"a6ecb8389c","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Lead Independent Director","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Stephen Farrell was appointed as Lead Independent Director at STAAR SURGICAL CO.","evidence_excerpt":"the Board announced creation of the role of Lead Independent Director and appointed Mr. Stephen Farrell, Chair of the Audit Committee, to serve in that capacity","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-039439","anchor_url":"https://secwatch.observer/filing/0001564590-22-039439#claim-a6ecb8389c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022039439/0001564590-22-039439-index.htm"},{"fact_type":"executive_change","fact_key":"8218437e74","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Thomas G. Frinzi was appointed as Chief Executive Officer at STAAR SURGICAL CO.","evidence_excerpt":"the Company announced that the Board elected Thomas G. Frinzi, currently Chair of the Board, to succeed Ms. Mason as CEO, effective January 1, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-039439","anchor_url":"https://secwatch.observer/filing/0001564590-22-039439#claim-8218437e74","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022039439/0001564590-22-039439-index.htm"},{"fact_type":"executive_change","fact_key":"1d71996451","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2022-12-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Thomas G. Frinzi","successor_named":true},"claim":"Caren Mason retired as President and Chief Executive Officer at STAAR SURGICAL CO.","evidence_excerpt":"Ms. Caren Mason, President and Chief Executive Officer of the Company, has elected to retire as CEO and a member of the Company’s Board of Directors (the “Board”), effective December 31, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-039439","anchor_url":"https://secwatch.observer/filing/0001564590-22-039439#claim-1d71996451","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022039439/0001564590-22-039439-index.htm"},{"fact_type":"earnings_release","fact_key":"9f2e3b158be589f366f8e8b7e886ef9f59637c76","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2022-11-02T23:59:59+00:00","payload":{"eps_text":"$0.21 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$10.3 million or $0.21 per diluted share","period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-02","result_type":"reported_results","revenue_text":"$76.0 million"},"claim":"STAAR SURGICAL CO reported the third quarter ended September 30, 2022 results: revenue $76.0 million, net income $10.3 million or $0.21 per diluted share, EPS $0.21 per diluted share. Guidance reaffirmed.","evidence_excerpt":"STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-036358","anchor_url":"https://secwatch.observer/filing/0001564590-22-036358#claim-9f2e3b158be589f366f8e8b7e886ef9f59637c76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022036358/0001564590-22-036358-index.htm"},{"fact_type":"executive_change","fact_key":"6d8c18a1e7","cik":718937,"ticker":"STAA","company_name":"STAAR SURGICAL CO","filed_at":"2022-07-20T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2022-07-31","interim":false,"role":"Sr. V.P., Commercial Operations, Direct Markets Europe and China","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Hans Blickensdoerfer departed as Sr. V.P., Commercial Operations, Direct Markets Europe and China at STAAR SURGICAL CO.","evidence_excerpt":"On July 15, 2022, Mr. Hans Blickensdoerfer, Sr. V.P., Commercial Operations, Direct Markets Europe and China informed STAAR Surgical Company (the “Company”) of his intention to retire, effective July 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-026053","anchor_url":"https://secwatch.observer/filing/0001564590-22-026053#claim-6d8c18a1e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/718937/000156459022026053/0001564590-22-026053-index.htm"}]}